In a notable turn of events for the IPO market, where AI-related stocks have faced headwinds, Scribe Therapeutics Inc. (SCTX.US), a CRISPR gene-editing company co-founded by Nobel Prize-winning chemist Jennifer Doudna, is generating strong demand on the Nasdaq. The clinical-stage biotechnology firm, which focuses on cardiovascular gene therapies, announced on Thursday that it priced 8.58 million shares at $15 each, successfully raising $128.7 million. This not only places the pricing at the top end of its range but also represents a significant increase from its initially planned offering size. This surge in investor interest coincides with the biotechnology sector outperforming AI-related IPOs, posting a weighted average return of 55% and emerging as a major winner in the US stock market for 2026.

IPO Details: Expanded Offering, Top-Tier Pricing, and Concurrent Sanofi Investment

Scribe Therapeutics first unveiled its IPO terms on July 21, planning to offer 7.2 million shares at a price range of $13 to $15 each, aiming to raise roughly $100 million. However, robust investor demand prompted the company to increase the offering. It ultimately sold 8.58 million shares at the peak of the range at $15 per share, bringing total proceeds to $128.7 million. According to an official Nasdaq announcement, the underwriters for this IPO have a 30-day option to purchase an additional 1.287 million shares. Leerink Partners, Goldman Sachs, Guggenheim Securities, and Wells Fargo are serving as joint book-running managers. Trading is set to begin on the Nasdaq Global Market on July 24 under the ticker symbol "SCTX," with the transaction expected to close on July 27.

Notably, French pharmaceutical giant Sanofi (SNY.US) is concurrently purchasing 500,000 shares through a private placement at the same price of $15 per share. Both Sanofi and Eli Lilly are existing strategic partners of Scribe. Eli Lilly (LLY.US), which already holds approximately 12.4% of Scribe shares, has indicated its intention to increase its stake in this IPO to maintain an ownership level of up to roughly 11% after the offering and placement are completed.

Technology Platform: Epigenetic Silencing – A CRISPR Therapy Without the 'Genetic Scissors'

Founded in 2017 by Doudna and CEO Benjamin Oakes, among others, Scribe Therapeutics distinguishes itself from traditional CRISPR gene editing through its use of an epigenetic silencing strategy. This approach employs an engineered CRISPR system to target specific genes and regulate their expression without permanently cutting or altering the DNA. The company claims this method offers significant safety advantages, potentially expanding the patient population eligible for treatment.

Scribe's lead drug candidate, STX-1150, targets the PCSK9 gene, a well-validated clinical target for cholesterol regulation. By epigenetically silencing PCSK9 gene expression, STX-1150 aims to achieve durable reductions in low-density lipoprotein cholesterol (LDL-C). In preclinical studies involving non-human primates, STX-1150 demonstrated up to 90% inhibition of PCSK9 and a maximum reduction in LDL-C of 68%, with even the lowest dose achieving over 50% LDL-C reduction that persisted for more than 22 months. STX-1150 has received approval from Australia's Therapeutic Goods Administration (TGA) to commence its first human clinical trial, a key milestone for Scribe as it advances into the clinical stage. This Phase I study is an open-label, single-dose escalation trial, with an expansion phase planned to enroll up to 64 participants at sites in Australia and New Zealand. The company anticipates releasing initial clinical data in the first half of 2027. Beyond STX-1150, Scribe has two additional pipeline programs, STX-1200 and STX-1400, which target lipoprotein(a) and triglycerides, respectively, with Phase I clinical trials expected to begin in 2027 and 2028.

Strategic Value: The Double Endorsement from Eli Lilly and Sanofi

The deep involvement of two major pharmaceutical companies provides significant credibility for Scribe's IPO. Eli Lilly has had a strategic partnership with Scribe since 2025, and the collaboration has already achieved a successful milestone for its second in vivo program. Sanofi, meanwhile, is investing $7.5 million to purchase shares through a concurrent private placement. Both pharmaceutical firms are not merely financial investors but are also key partners in validating Scribe's technology platform and potential commercialization pathways.

From a financial perspective, Scribe generated approximately $36 million in collaboration revenue over the twelve months ending March 31, 2026, an uncommon achievement for a clinical-stage biotech company with no approved products on the market. However, the company remains in a net loss position. In the quarter ending March 31, 2026, Scribe reported collaboration revenue of $2.2 million and a net loss of $17.4 million, compared to collaboration revenue of $17.1 million and a net loss of $3.5 million in the same period last year. The company estimates in its filing that proceeds from the IPO and private placement will be sufficient to fund its operations and capital expenditures through the first half of 2029.

Sector Context: Biotech IPOs Outperform with 55% Returns

Scribe Therapeutics' successful listing is not an isolated event but reflects a broader recovery in the biotech IPO market in 2026. Data indicates that US biotech and pharmaceutical IPOs this year have posted a weighted average return of 55%. In contrast, the overall US IPO market, excluding financial instruments like SPACs, has seen a weighted average return of negative 4.4%. This disparity means the biotech sector has outperformed the broader market by nearly 60 percentage points.

Meanwhile, the once highly anticipated AI-related IPOs have performed poorly. The ten largest US IPOs in 2026, led by SpaceX's record-breaking listing, have experienced a weighted average share price decline of 6.3%, fueling concerns that the AI rally may be overextended. "This is the healthiest biotech IPO market we've seen in a long time," said Jack Bannister, Managing Director of Equity Capital Markets at Leerink Partners. The strong performance in the biotech sector is attributed to several factors, including a 13% year-to-date increase in the Nasdaq Biotechnology Index, a more stable regulatory environment, and heightened investor interest in platform companies with clear clinical pathways and substantial addressable markets. At least six other biotech companies, led by CRISPR gene drug developer Scribe, have filed for IPOs in July and are expected to price by late summer.